<DOC>
	<DOCNO>NCT00517699</DOCNO>
	<brief_summary>This study evaluate efficacy safety MabThera plus high dose methotrexate plus high dose cytarabine patient central nervous system non-Hodgkin 's lymphoma . Eligible patient receive treatment regimen consist MabThera ( 750mg/m2 iv ) plus methotrexate ( 8g/m2 iv ) give interval week 22 , plus cytarabine ( 2g/m2 iv ) week 11 week 22 . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Primary Central Nervous System Lymphoma .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>adult patient , 1880 year age ; histological diagnosis primary central nervous system lymphoma ; Bcell proliferation verify positive staining CD20 ; &gt; =1 measurable lesion . prior chemotherapy , corticosteroid , &gt; =6 week diagnosis surgery ; history prior cranial irradiation ; evidence plurisystemic nonHodgkin 's lymphoma ; active malignant disease ( basal cell squamous cell cancer skin , cancer situ cervix ; uncontrolled active infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>